Cargando…
Population pharmacokinetics of tenofovir, emtricitabine and intracellular metabolites in transgender women
AIMS: Transgender women (TGW) have been underrepresented in trials and use gender‐affirming hormonal therapies (GAHT) that may alter renal function by significantly increasing creatinine clearance. Population pharmacokinetic (popPK) models and simulations would aid in understanding potential differe...
Autores principales: | Tanaudommongkon, Asama, Chaturvedula, Ayyappa, Hendrix, Craig W., Fuchs, Edward J., Shieh, Eugenie, Bakshi, Rahul P., Marzinke, Mark A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9296590/ https://www.ncbi.nlm.nih.gov/pubmed/35285974 http://dx.doi.org/10.1111/bcp.15310 |
Ejemplares similares
-
Transgender women on oral HIV pre‐exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men
por: Shieh, Eugenie, et al.
Publicado: (2019) -
Population pharmacokinetics of tenofovir and tenofovir‐diphosphate in healthy women
por: Burns, Rebecca N., et al.
Publicado: (2015) -
Linking the Population Pharmacokinetics of Tenofovir and Its Metabolites With Its Cellular Uptake and Metabolism
por: Madrasi, K, et al.
Publicado: (2014) -
Clinical trial simulation to evaluate tenofovir disoproxil fumarate/emtricitabine HIV pre-exposure prophylaxis dosing during pregnancy
por: Scott, Rachel K., et al.
Publicado: (2023) -
Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates
por: Chen, Xinhui, et al.
Publicado: (2016)